← Leaderboards
Jun Yang
St. Jude Children'S Research Hospital
$3,072,061
Attributed
$6,012,346
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,012,346 · 5
By mechanism
R01$5,832,846 · 4
R03$179,500 · 1
Top collaborators
- Taosheng Chen4 shared
- Xiang Chen4 shared
- Andrew M Davidoff4 shared
- Stephen W White4 shared
- Kevin W. Freeman1 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Michael A Dyer$24,988,379
- Mark Edward Hatley$4,899,188
- Janet Anne Houghton$8,199,871
- James R Downing$3,840,185
- Stephen X Skapek$24,951,237
Others in their field
Other Emerging Leaders on “Epigenetic Process”
- Michael-Christopher Keogh · Epicypher, Inc.$20,096,362
- Barbara Halina Braffett · George Washington University$9,972,097
- Ionut Bebu · George Washington University$9,972,097
- Jennifer Cohen Price · University Of California, San Francisco$9,197,178
- Scott Topper · Broad Institute, Inc.$8,965,812
- Ruchir Shah · Sciome, Llc$7,820,780
Research focus
Epigenetic ProcessTranscription FactorGenetic TranscriptionOncogenicMalignant NeoplasmsTumorigenesisMalignant Childhood NeoplasmHistonesHistone DemethylaseProgramsLysinePlayIn VitroCancer CellIn VivoNeoplasm MetastasisTranslatingPre-ClinicalMethylationOncoproteinsCellsMolecularFamilySmall Molecule
Grant awards (12)
Targeting splicing vulnerability of neuroblastoma$767,328
R01 · FY2025 · CA · contact PI
Targetable epigenetic modifiers that promote neuroblastoma malignancy and plasticity$718,113
R01 · FY2025 · CA · contact PI
EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA$691,425
R01 · FY2025 · CA · contact PI
EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA$656,854
R01 · FY2024 · CA · contact PI
EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA$677,596
R01 · FY2023 · CA · contact PI
EXPLORE AND TARGET THE EPIGENETIC VULNERABILITY OF PAX3-FOXO1-DRIVEN RHABDOMYOSARCOMA$691,425
R01 · FY2022 · CA · contact PI
Development of small molecules to target KDM4B$410,606
R01 · FY2021 · CA · contact PI
Development of small molecules to target KDM4B$410,606
R01 · FY2020 · CA · contact PI
Development of small molecules to target KDM4B$398,287
R01 · FY2019 · CA · contact PI
Development of small molecules to target KDM4B$410,606
R01 · FY2018 · CA · contact PI
The role of JMJD6 in MYC-mediated neuroblastoma$89,750
R03 · FY2018 · CA · contact PI
The role of JMJD6 in MYC-mediated neuroblastoma$89,750
R03 · FY2017 · CA · contact PI